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Abstract
Background: Travellers’ diarrhoea (TD) is the most common infectious disease among travellers. In the
Netherlands, stand-by or prophylactic antibiotics are not routinely prescribed to travellers. This study prospectively
assessed the incidence rate, risk factors, and treatment of TD among immunocompetent travellers.
Methods: Persons who attended the travel clinic of the Public Health Service Amsterdam in 2006-2007 before
short-term travel to tropical and subtropical countries were invited to answer a questionnaire regarding
sociodemographics and travel purpose; they were also asked to keep a daily structured travel diary, recording their
itinerary, symptoms, and self-medication or consultation with a doctor. Diarrhoea episodes containing blood or
mucous were considered severe.
Results: Of 1202 travellers, the median age was 38 years, and the median travel duration 3 weeks. Of all episodes,
96% were mild. The median duration of TD was 2 days and significantly shorter in subsequent episodes compared
to first episodes (p < 0.0005). Of first episodes 38% started in the first travel week. The incidence rate (IR) for first
episodes was 2.49 (95% confidence interval [CI], 2.30-2.70) per 100 travel days, with the highest IR among travellers
to South-Central and West Asia. The IR for first and subsequent episodes was comparable. Risk factors for first
episodes included female sex, a Western country of birth, and tourism as the purpose of travel. The lowest risk was
in travellers to South America. An independent risk factor for subsequent episodes was female sex. In total, 5% of
travellers used antibiotics; of those, 92% had mild diarrhoea, and 53% received antibiotics over the counter.
Conclusions: TD is common among travellers, but the overall course is mild, not requiring treatment. The
incidence rates for first and second episodes are comparable. Female sex is a risk factor for the first episode, as
well as subsequent ones. Prescription antibiotics are not needed in short-term healthy travellers.
Background
International tourism in 2007 showed approximately 908
million tourist arrivals worldwide [1]. Among tourists
from industrialized countries, about 80 million crossed
the borders of tropical and subtropical countries, many
of which are developing areas, each year [2]. The most
common infectious health problem among travellers
from industrialized regions to developing countries is
travellers’ diarrhoea (TD) [2-11]. Because of the
continuing high rates of international travel, TD will
continue to be an important problem.
The annual number of Dutch travellers to tropical and
subtropical countries doubled from approximately 1 mil-
lion in 1999 to about 2 million in 2007 [12]. The Neth-
erlands has a restrictive antibiotic policy and, therefore,
low microbial resistance patterns [13-15]. The Dutch
national guidelines for traveller’s health advice do not
advise everyone to carry stand-by treatment, only those
at increased risk, such as immunocompromised persons
and travellers to very remote areas [16].
In this prospective study we estimated the attack rate
and incidence rate and studied risk factors and
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tent, short-term travellers to tropical and subtropical
countries. Further, we described treatment and the
severity of episodes.
Methods
Study population
A prospective study recruited persons attending the tra-
vel clinic of the Public Health Service Amsterdam from
October 2006 to October 2007 [17]. All immunocompe-
tent persons 18 years and older were eligible if they
were planning to travel for 1 to 13 weeks to one or
more developing countries. Based on the definition by
the United Nations, Department of Economics and
social affairs [18], we categorized these countries in 6
regions: South America; Central America and Carib-
bean; Middle, Western and Northern Africa; Southern
and Eastern Africa; South-Eastern and Eastern Asia; and
South-Central and Western Asia (Figure 1). Those who
reported a history of immunosuppressive disorder, with
functional gastrointestinal disorders, and pregnant
women were excluded.
All participants were seen by a medical doctor or
nurse specialised in travel medicine. Based on Dutch
national guidelines on traveller’s health advice, they
received vaccinations, a prescription for antimalarial
chemoprophylaxis if required, and oral and written
information about how to avoid acquiring travel-related
diseases including diarrhoea, such as good personal
hygiene and sanitary conditions and avoiding unsafe
water and food. For diarrhoea, travellers were advised to
carry an antimotility agent and oral rehydration solu-
tion. Cholera vaccine is not indicated, according to the
guidelines. Antibiotics, which cannot be purchased with-
out a prescription in the Netherlands, are only pre-
scribed for the treatment of TD to those at increased
risk, and thus, a prescription for these immunocompe-
tent travellers was not provided.
Survey methods
A standard questionnaire in Dutch or English was used
to collect data before departure on sociodemographics,
travel history and purpose of the travel (tourism, work
or education, or visiting friends and/or relatives). Partici-
pants were given a thermometer (ordered 2006, Cemex,
Bleiswijk, The Netherlands) and asked to take their tem-
perature when feeling feverish. They were also asked to
keep a structured travel diary, recording symptoms, itin-
erary, and signs of disease, such as a gastrointestinal dis-
order (diarrhoea, fever, vomiting, bloody or mucous
Figure 1 UN classification of the world, in regions (2002).
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Page 2 of 9stools or other symptoms) and possible self-treatment or
involvement of a doctor during a diarrhoeal episode.
Participants made daily diary entries from the day they
arrived at their destination to 1 week after their return,
to encompass incubation periods of diarrhoea. Thus,
‘travel-related’ in our study refers to the period of travel
and one week thereafter. Travel duration was recorded
as the total days spent in areas meeting the inclusion
criteria. All participants were seen between 2 and 6
weeks after return, when the diary was checked by a
registered nurse in the participant’s presence. Partici-
pants received a gift voucher of 25€ for completing the
study. The study protocol was approved by the Medical
Ethics Committee of the Academic Medical Center
Amsterdam. Participants were included only with
informed and written consent.
Definitions
Diarrhoeal episodes were regarded as TD when they met
the definition of the World Health Organization [19]
(any episode of any number of more frequent passage of
loose or liquid stools per day than is normal for the
individual from the beginning of the journey to the end
of the first week after return). An episode was regarded
as severe when the diarrhoea contained blood, mucous,
or both. The episodes were considered separate if they
were at least 5 days apart [3]. Age was categorized in 3
groups, because age 18-30 years was shown to be a risk
factor for TD [6,11]. Travellers older then 30 years were
divided into two other age groups (31 - 45 and 46 - 80
years).
Data analysis
Data analysis was performed with SPSS version 17.0.2
(2009, IBM, Somers, USA) and version 19.0.0.1 (2010),
Stata statistical software, version 11 (Statacorp, College
Station, USA) and OpenEpi (version 2.3, May 2009,
Andrew G. Dean and Kevin M. Sullivan, Atlanta, USA).
Incidences were expressed both as attack rates (ARs)
and as incidence rates (IRs). Attack rates were calcu-
lated by dividing the number of persons reporting epi-
sodes of TD by the total number of persons at risk.
Incidence rates per 100 travel days for the first episode
were calculated by dividing the number of first epi-
sodes by the total number of travel days in which par-
ticipants were at risk for a first episode. Incidence
rates for subsequent episodes were calculated by divid-
ing the number of second or later episodes by travel
days at risk. Only travellers who had experienced a
first episode contributed to this analysis, and time at
risk started 5 days after the last day of the first epi-
sode. Travel destination was treated as a variable with
six categories, the reference category being the geogra-
phical region with the lowest attack rate for TD.
Independent risk factors were identified by multiple
logistic regression analysis and univariate and multi-
variate Poisson analysis. Both in the univariate analysis
and the multivariate analysis, associations were
expressed as incidence rate ratios. Age and sex were
forced into the Poisson model. A p-value < 0.05 was
considered statistically significant.
Results
Study population
Between October 2006 and October 2007 1276 subjects
w h oi n t e n d e dt ot r a v e lt ot h ed e v e l o p i n gw o r l dp r o -
vided informed consent. Of these, 74 (6%) were
excluded after the study ended: 23 had their travel
arrangements cancelled and 42 were lost to follow-up.
For this study we excluded 9 other subjects: 5 with
functional gastro-intestinal disorders, 3 pregnant
women, and 1 with an immune disorder. The remaining
1202 formed the study population (characteristics are
s h o w ni nT a b l e1 ) .T h em e d i a na g ew a s3 8y e a r s( 4 0
for men, 37 for women). The vast majority were native
Dutch tourists travelling on holiday; 8% travelled for
work or education, and 6% were visiting friends or rela-
tives. The median travel duration was 3 weeks. The
most frequently visited continent was Asia (47%); 28%
travelled to Latin America and 25% to Africa. Most of
the 1202 travellers had visited subtropical and tropical
countries before (979, 81%).
Attack rates and incidence rates
Of all 1202 travellers, 597 (AR 50%, 95% CI 47-52)
experienced one or more episodes of diarrhoea (Table
2). In total, 781 episodes were reported by 597 travellers.
Most of the 1202 travellers (450, 37%) reported only 1
episode; 121 (10%) reported 2 episodes, 19 (2%) 3 epi-
sodes, 3 (0.2%) 4 episodes, and 4 (0.3%) reported 5 epi-
sodes. Both the attack rate and the incidence rate for
the first episode were highest in travellers to South-Cen-
tral and Western Asia (the Indian subcontinent) (AR:
62%; IR: 3.83 per 100 travel days [95% CI 3.07 - 4.77]).
Independent risk factors for a first episode of TD were:
female sex, a Western country of birth, travel as a tour-
ist as compared to visiting friends and relatives, and tra-
vel to South-Central and Western Asia (the Indian
subcontinent), Central America and Caribbean, and
Middle, Western and Northern Africa as compared to
South America.
The median duration of both the first and subsequent
episode was 2 days (IQRfirst episode 1-6, IQRsubsequent epi-
sode 1-3; p < 0.0005).
The incidence rates for first and subsequent episodes
were comparable; 2.49 (95% CI 2.30 - 2.70) for first epi-
sodes (Table 2) and 2.75 (95% CI 2.38 - 3.18) for subse-
quent episodes (Table 3).
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Page 3 of 9Of first episodes, 228 out of 597 (38%) started in the first
travel week, and most of the subsequent episodes (113 out
of 184, 61%) started after the third week of travel. Time
until the first episode of TD is shown in Figure 2.
The incidence rate for subsequent episodes was high-
est in Middle, Western, and Northern Africa (4.89, 95%
CI 3.33 - 7.18) (Table 3). The only independent risk fac-
tor for a subsequent episode of TD was female sex (IRR
1.50, 95% CI 1.09 - 2.04) (Table 3).
During first episodes of TD, fever was reported by 85
of 597 subjects (14%), vomiting by 75 (13%), nausea by
5 (6%), and abdominal cramps by 31 (5%). During sub-
sequent episodes of TD in 184 cases, fever was reported
by 20 (11%), vomiting by 11 (6%), nausea by 18 (10%),
and abdominal cramps by 12 (7%). No accompanying
symptoms were reported in 428 (72%) of first episodes
and in 137 (75%) of subsequent episodes. Of all 781 TD
episodes, 29 (4%) were considered severe, and the attack
rates of severe TD were not different for first and subse-
quent episodes (p = 0.940; ARfirst episodes 4% (22/597),
ARsubsequent episodes 4% (7/184)). None of the variables
we examined were associated with severe episodes of
TD.
Treatment
Of all 781 subjects with episodes of diarrhoea, 464 (59%)
took no treatment, 231 (30%) used an antimotility agent
such as loperamide, 116 (15%) oral rehydration solution
(ORS), and 36 (5%) antibiotic treatment: 33 out of 752
(5%) for mild TD and 3 of 29 (10%) for severe TD
(Table 4). Of the 36 subjects that used antibiotic treat-
ment, 18 also used an antimotility agent, for mild diar-
rhoea. Of all 781 travellers who had TD, 25 (3%)
consulted a physician, including 2 with severe disease.
For 17 out of the 25 who sought medical treatment,
local physicians prescribed antibiotics. The other 19
subjects (53%) who used antibiotics bought them over
the counter.
Discussion
Despite the pre-travel advice on personal hygiene mea-
sures to prevent travellers’ diarrhoea, it still occurred in
half of all travellers. Compliance with these measures
and, therefore, the effectiveness of the recommendations
has been found to be poor [6,20]. The high risk of TD
found in our study is comparable with earlier prospec-
tive studies, which have found attack rates to vary
between 25% and 57% [4,9,11,21,22].
In our study, the IR and AR were highest in South-
Central (the Indian subcontinent) and Western Asia, fol-
lowed by Middle, Western and Northern Africa and
Central America and the Caribbean. Most other studies
have also found the Indian subcontinent to be a high-
risk area, followed by African regions [2-4,9,11,23,24].
Findings of AR and IR in different regions within Latin
America differ between studies [3,4,9,11,23,24]. How-
ever, comparing risk patterns between destinations in
various studies is difficult, because of differing study
Table 1 Characteristics of a prospective cohort of 1202
travellers to developing countries who attended a Dutch
travel health clinic for pre-travel advice, October 2006 -
October 2007
Number of subjects 1202
Male sex 520 43%
Median age in years° 38 29-51
Age groups in years
18 - 30 394 33%
31 - 45 379 32%
46 - 80 429 36%
Country of birth
Netherlands 1048 87%
Other Western country 67 6%
Non-Western country 87 7%
Previous travel to a developing country
Never 223 19%
1 - 5 times 698 58%
6 times or more 281 23%
Previous travel destinations*
1
Asia 664 55%
Latin America 543 45%
Africa 524 44%
Primary purpose of travel
Tourism 1030 86%
Work or education 98 8%
Visiting friends and/or relatives 74 6%
Current travel destination (regions)
South-Eastern and Eastern Asia 422 35%
South-Central and Western Asia 127 11%
South America 202 17%
Central America and Caribbean 120 10%
Southern and Eastern Africa 184 15%
Eastern Africa 119 10%
Southern Africa 45 4%
Both Eastern and Southern Africa 20 2%
Middle, Western and Northern Africa 111 9%
Several regions*
2 33 3%
Several continents*
2 3
Median travel duration in days° 21 15-28
< 21 days 527 44%
21-34 days 533 44%
≥ 35 days 142 12%
° Interquartile range in second column
*
1 Does not add up to 100%, because persons travelled to more than one continent
*
2 Visited more than 1 region or continent during travel
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Page 4 of 9Table 2 Attack rates, incidence rates and predictors of first episodes of TD in a prospective cohort of 1202 travellers
from the Netherlands to developing countries, October 2006 - October 2007
≥ 1TD
episode
Attack
rate
Person-
days of
travel
Crude Incidence
Rate per 100 travel
days (95%CI)
Incidence Rate
Ratio, univariate
(95%CI)
P value Incidence Rate
Ratio,
multivariate
(95%CI)
P value
Total 1202 597 50% 23 959 2.49 (2.30 - 2.70)
Sex
Male 520 236 45% 10714 2.20 (1.94 - 2.50) 1.00 0.011 1.00 0.013
Female 682 361 53% 13245 2.73 (2.46 - 3.02) 1.24 (1.05 - 1.46) 1.23 (1.04 - 1.46)
Age group, years
18-30 394 220 56% 7663 2.87 (2.52 - 3.28) 1.00 0.023 1.00 0.058
31-45 379 171 45% 7846 2.18 (1.88 - 2.53) 0.76 (0.62 - 0.93) 0.78 (0.64 - 0.96)
46-80 429 206 48% 8450 2.44 (2.13 - 2.80) 0.85 (0.70 - 1.03) 0.87 (0.72 - 1.06)
Country
of birth
Netherlands 1048 535 51% 20517 2.61 (2.40 - 2.84) 1.00 0.003 1.00 0.009
Other Western
country
67 34 51% 1487 2.29 (1.63 - 3.20) 0.88 (0.62 - 1.24) 0.83 (0.59 - 1.18)
Non-Western
country
87 28 32% 1955 1.43 (0.99 - 2.08) 0.55 (0.38 - 0.80) 0.58 (0.39 - 0.86)
Primary purpose of travel
Tourism 1030 518 50% 20306 2.55 (2.34 - 2.78) 1.00 0.005 1.00 0.032
Work or
education
98 53 54% 1854 2.86 (2.18 - 3.74) 1.12 (0.85 - 1.49) 1.12 (0.84 - 1.51)
Visiting friends
and/or
relatives
74 26 35% 1799 1.45 (0.98 - 2.12) 0.57 (0.38 - 0.84) 0.63 (0.42 - 0.94)
Previous travel to a
developing country
Never 223 118 53% 4178 2.82 (2.36 - 3.38) 1.00 0.109
1 to 5 times 698 351 50% 13881 2.53 (2.28 - 2.81) 0.90 (0.73 - 1.10)
6 times or
more
281 128 46% 5900 2.17 (1.82 - 2.58) 0.77 (0.60 - 0.99)
Travel destination
Latin
America
South America 202 88 44% 4483 1.96 (1.59 - 2.42) 1.00 < 0.0005 1.00 < 0.0005
Central
America and
Caribbean
120 66 55% 2014 3.28 (2.58 - 4.17) 1.67 (1.21 - 2.30) 1.54 (1.12 - 2.13)
Africa Southern and
Eastern Africa
184 85 46% 3804 2.24 (1.81 - 2.76) 1.14 (0.85 - 1.53) 1.10 (0.82 - 1.49)
Middle,
Western and
Northern
Africa
111 62 56% 1747 3.55 (2.77 - 4.55) 1.81 (1.31 - 2.50) 1.93 (1.39 - 2.68)
Asia South-Eastern
and Eastern
Asia
422 199 47% 8811 2.26 (1.97 - 2.60) 1.15 (0.90 - 1.48) 1.11 (0.87 - 1.43)
South-Central
and Western
Asia
127 79 62% 2063 3.83 (3.07 - 4.77) 1.95 (1.44 - 2.64) 1.94 (1.43 - 2.64)
Several
regions
Several regions 33 15 46% 975 1.54 (0.93 - 2.55) 0.78 (0.45 - 1.36) 0.75 (0.44 - 1.30)
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regions. The regional variations in AR and IR may be
due to differences in circulating pathogens [8] and in
hygienic standards between countries [25].
Of all 781 episodes of TD in our study, only 29 (4%)
were considered severe, as defined by blood and/or
mucous content. Possibly these episodes were caused by
one of the invasive pathogens, like Campylobacter jejuni,
Table 3 Incidence rates of and predictors for acquiring 2
nd or later TD episodes among 597 travellers in a prospective
cohort from the Netherlands to developing countries, October 2006 - October 2007
Diarrhoea Subsequent
episodes
Person-
days of
travel
Crude Incidence Rate
per 100 travel days
(95%CI)
Incidence Rate
Ratio, univariate
(95%CI)
P
value
Incidence Rate
Ratio, multivariate
(95%CI)
P
value
Total 184 6690 2.75 (2.38 - 3.18)
Sex
Male 57 2687 2.12 (1.64 - 2.75) 1.00 0.010 1.00 0.009
Female 127 4003 3.17 (2.67 - 3.78) 1.50 (1.09 - 2.04) 1.50 (1.10 - 2.05)
Age group, years
18-30 80 2945 2.72 (2.18 - 3.38) 1.00 0.534 1.00 0.504
31-45 45 1824 2.47 (1.84 - 3.30) 0.91 (0.63 - 1.31) 0.93 (0.65 - 1.34)
46-80 59 1921 3.07 (2,38 - 3,96) 1.13 (0.81 - 1.58) 1.16 (0.83 - 1.63)
Country of birth
Netherlands 168 6091 2.76 (2.37 - 3.21) 1.00 0.555
Other Western
country
10 294 3.40 (1.83 - 6.32) 1.23 (0.65 - 2.33)
Non-Western
country
6 305 1.97 (0.88 - 4.38) 0.71 (0.32 - 1.61)
Primary purpose of travel
Tourism 156 5649 2.76 (2.36 - 3.23) 1.00 0.658
Work or
education
24 823 2.92 (1.96 - 4.35) 1.06 (0.69 - 1.62)
Visiting friends
and/or relatives
4 218 1.84 (0.69 - 4.89) 0.66 (0.25 - 1.79)
Previous travel to a
developing country
Never 25 1344 1.86 (1.26 - 2.75) 1.00 0.069
1 to 5 times 122 4082 2.99 (2.50 - 3.57) 1.61 (1.05 - 2.47)
6 times or more 37 1264 2.93 (2.12 - 4.04) 1.57 (0.95 - 2.61)
Travel destination
Latin
America
South America 27 875 3.09 (2.12 - 4.50) 1.00 0.064
Central America
and Caribbean
8 472 1.70 (0.85 - 3.39) 0.55 (0.25 - 1.21)
Africa Southern and
Eastern Africa
29 1098 2.64 (1.84 - 3.80) 0.86 (0.51 - 1.45)
Middle, Western
and Northern
Africa
26 532 4.89 (3.33 - 7.18) 1.58 (0.92 - 2.71)
Asia South-Eastern
and Eastern Asia
69 2625 2.63 (2.08 - 3.33) 0.85 (0.55 - 1.33)
South-Central
and Western Asia
18 871 2.07 (1.30 - 3.28) 0.67 (0.37 - 1.22)
Several
regions
Several regions 7 199 3.52 (1.68 - 7.38) 1.14 (0.50 - 2.62)
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Page 6 of 9shigella or salmonella species. As in other studies, most
TD episodes were mild. Cobelens et al. [3] found fecal
blood loss and concomitant abdominal and systemic
symptoms in subsequent episodes more often than in
first episodes and subsequent episodes lasted longer
than first. However, we found no difference in severity
of TD between first and subsequent episodes and subse-
quent episodes had a significant shorter median dura-
tion than first episodes. Because it is unlikely that
exposure to pathogens decreases, this could possibly
mean that travellers acquire immunity to some patho-
gens, similar to people born in non-Western countries.
Baaten et al. [25] found that the incidence of other
feco-orally transmitted infections like hepatitis A, shigel-
losis, and typhoid fever among travellers declined in the
past 10 years, which seemed related to an increase in
hygienic standards in the destination countries. On that
basis, we would expect the incidence of TD to have
declined over the last decades. Indeed, the overall inci-
d e n c er a t eo fT Di no u rs t u d yo f2 . 4 9p e r1 0 0t r a v e l
days (95% CI 2.30 - 2.70) was significantly lower
compared to the IR of 3.14 per 100 travel days (95% CI
2.86 - 3.43) observed 10 years ago among travellers in
Amsterdam [3]. However, these two studies were differ-
ent in some respects. First, because the travellers in our
study had different travel patterns, we defined somewhat
larger regions. Second, we used the WHO definition of
TD, whereas Cobelens defined TD as any episode of 3
or more unformed stools daily or any number of such
bowel movements accompanied by vomiting, abdominal
cramps, or subjective fever, with an onset between the
beginning and end of the journey. Finally, our study was
prospective, with travellers asked to record symptoms
daily in a diary, whereas Cobelens’ study was retrospec-
tive, and thus may be subject to recall bias. Although
we cannot conclude that the IR of TD has actually
decreased, the finding of a lower IR with a broader defi-
nition could indicate that it is indeed declining.
Independent risk factors for first episodes of TD in
our study were female sex, a Western country of birth,
tourism as the purpose of travel, and some travel desti-
nations. Also, female sex was an independent risk fac-
tor for subsequent episodes of TD. Sex differences in
travel-associated disease and diarrhoea have been
reported previously [26], but it is unclear if this differ-
ence can be explained by different travel behavior or
by women being more susceptible to diarrhoea or
more likely to report diarrhoea. Birth in a non-Wes-
tern country may confer immunity to TD because of
increased exposure to infections endemic in those
countries [2,27]. Several studies have shown an
increased risk of TD in younger age groups [5,6,9]; we
also found an association between younger age and the
risk of TD, although not significant.
To our knowledge, our study is the first to calculate
IR for subsequent episodes. Incidence rates did not dif-
fer between the development of a first episode of TD
and a later episode, and neither did we find differences
in severity between the first and subsequent episodes.
Apparently, having had an episode of diarrhoea is not
protective for a subsequent episode. Although antibiotic
Table 4 Treatment for travellers diarrhoea in a prospective cohort of 1202 travellers from the Netherlands to
developing countries, October 2006 - October 2007
Treatment Total episodes 1st episode 2nd and subsequent episodes
mild severe mild severe
Total 781 575 (96%) 22 (4%) 177 (96%) 7 (4%)
No treatment 464 59% 327 (57%) 11 (44%) 123 (70%) 3 (43%)
Antimotility agents 231 30% 178 (31%) 7 (32%) 46 (26%) 0
ORS 116 15% 92 (16%) 6 (27%) 16 (9%) 2 (29%)
Antibiotic 36 5% 30 (5%) 1 (5%) 3 (2%) 2 (29%)
Alternative antidiarrhoeal drugs 22 3% 18 (3%) 1 (5%) 3 (2%) 0
Visited physician for diarrhoea 25 3% 18 (3%) 1 (5%) 5 (3%) 1 (14%)
0
.
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2
5
0
.
5
0
0
.
7
5
1
.
0
0
0 1 2 3 4 5 6 7 8
Time after departure (in weeks)
Figure 2 Kaplan-Meier graph of diarrhoea-free survival among
1202 short-term travellers from the Netherlands to developing
countries, 2006-7. Time is indicated in weeks and data censored at
7 weeks.
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Page 7 of 9stand-by treatment was not prescribed before travel,
only 5% of travellers with TD resorted to antibiotics
purchased locally. Prescribing them to all would leave
millions of courses of unused antibiotics in circulation.
Aside from the unnecessary cost to travellers, public
health services, and/or insurers, improper use can con-
tribute to increased antimicrobial resistance.
Some people might argue that the use of antibiotics
would result in a shorter duration of diarrhoea, as was
found in a recent Cochrane meta-analysis [28]. The end-
point of this placebo controlled analysis was duration of
diarrhoea less than 72 hours, and severity. As our study
showed an overall mild course of TD, and a short median
duration of TD of 48 hours, it remains questionable
whether antibiotics would have benefited our group of
travellers, especially since the occurrence of side effects
of antibiotics as shown by the same analysis.
The strength of our study is that it is prospective,
which is the best approach for estimating attack rates
and incidence rates of travellers’ diarrhoea. Another
strength is the daily diary entries, which minimizes
recall bias. Our study also had some possible limitations.
We used the WHO definition of TD (any number of
more frequent passage of loose or liquid stools per day
than is normal for the individual), and asked for accom-
panying symptoms to define the severity of diarrhoea.
We did not ask participants to record the frequency of
stools per 24 hr nor the degree of disability that travel-
lers experienced, which would have possibly allowed us
to make more detailed analyses and compare our results
with more studies. On the other hand, asking holiday
makers to fill out too many details could lead to less
compliance with our study.
Conclusions
Diarrhoea is still a very frequently contracted infectious
disease by travellers, but the overall course of TD appears
to be mild, not requiring treatment. Prescriptions for
stand-by antibiotics should be limited to travellers at
high risk, such as those who are immunocompromised or
are visiting very remote areas.
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